Novartis Withdraws Arzerra CLL Second-Line Use Filing in EU
Executive Summary
Novartis has withdrawn its label extension application in Europe for use of Arzerra in combination with bendamustine for the treatment of relapsed chronic lymphocytic leukemia, following CHMP queries over a lack of comparable data.